Compare Mesoblast Limited (MESO) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Advanced Drainage Systems Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Advanced Drainage Systems Inc trades at $143.04 (market cap $10.96B). The key difference: Advanced Drainage Systems Inc is far larger — about 5.1× Mesoblast Limited's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMS | |
|---|---|---|
Market Cap | $2.17B | $10.96B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $175.38 |
52-Week Low | $12.88 | $110.99 |
Enterprise Value | $2.17B | $12.53B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
WMS trades at $142.93, down 3.13% today, with a neutral technical signal and mixed analyst sentiment. The company shows strong profitability with a 13.98% net income margin and 24.02% ROE, though revenue remained flat at $2.90B in 2025. Recent earnings beats and a dividend increase signal management confidence, while cash flow turned negative due to increased investing activities.
The outlook is cautiously optimistic with a consensus price target of $184.43 offering 29% upside. Risks include volatile cash flows and competitive pressures, but consistent earnings outperformance and solid balance sheet strength support a favorable risk-reward profile for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
